New Pancreatic Cancer Drug Doubles Survival Time in Trial

People with pancreatic cancer just got their first real breakthrough in decades, and the results are stunning enough to change how doctors treat this devastating disease.

Revolution Medicines announced Monday that its daily pill, daraxonrasib, helped patients live for 13.2 months compared to just 6.7 months with standard chemotherapy. That's an extra 6.5 months of life, nearly double the typical survival time.

The drug also slashed the risk of death by 60% in patients whose cancer had already progressed on other treatments. These results came from a Phase 3 trial, the final major testing stage before seeking FDA approval.

"These are dramatic, practice-changing outcomes," said RevMed CEO Mark Goldsmith. He called the results unprecedented, noting that no drug has ever shown a survival benefit greater than one year in a Phase 3 trial for pancreatic cancer.

Pancreatic cancer remains one of the deadliest diseases, with only 13% of patients surviving five years after diagnosis. It's aggressive, hard to detect early, and has resisted most treatment advances that have helped other cancers.

Daraxonrasib works differently than traditional chemotherapy. The pill targets RAS mutations, genetic changes that fuel tumor growth and appear in about 90% of pancreatic cancer cases.

The Ripple Effect

This breakthrough could transform treatment for thousands of families facing a diagnosis that has long felt like a death sentence. Beyond pancreatic cancer, the drug's success targeting RAS mutations opens doors for treating other cancers driven by the same genetic changes.

Revolution Medicines plans to use a Commissioner's National Priority Voucher to speed up FDA review, potentially bringing the drug to patients within months instead of years. The company is also testing the pill in newly diagnosed patients, which could expand its impact even further.

The drug showed manageable side effects, with rash being the most notable. While any side effect matters, doctors and patients dealing with pancreatic cancer have had few options beyond harsh intravenous chemotherapy until now.

Investors recognized the magnitude of these results too. Revolution Medicines' stock jumped more than 30% Monday as the news spread.

For the first time in years, families facing pancreatic cancer have genuine reason for hope.